别名 雄激素受体、AIS、Androgen receptor + [11] |
简介 Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues (PubMed:19022849). Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Lacks the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
Lacks the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones. |
靶点 |
作用机制 AR拮抗剂 [+1] |
在研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2024-01-05 |
靶点 |
作用机制 AR拮抗剂 |
在研机构 |
原研机构 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2022-06-28 |
靶点 |
作用机制 AR拮抗剂 |
在研机构 |
原研机构 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 巴拉圭 |
首次获批日期2021-07-16 |
开始日期2025-11-01 |
申办/合作机构 |
开始日期2025-01-15 |
申办/合作机构 |